玛巴洛沙韦治疗儿童流感的有效性。 - Suppr

Suppr

超能文献

Effectiveness of baloxavir marboxil against influenza in children.

作者信息

Kakuya Fujio, Haga Syunsuke, Okubo Hitoshi, Fujiyasu Hiroaki, Kinebuchi Takahiro

机构信息

Department of Pediatrics, Furano Kyokai Hospital, Furano, Hokkaido, Japan.

Department of Clinical Laboratory, Furano Kyokai Hospital, Furano, Hokkaido, Japan.

出版信息

Pediatr Int. 2019 Jun;61(6):616-618. doi: 10.1111/ped.13855. Epub 2019 Jun 13.

DOI:10.1111/ped.13855

PMID:31195429

Abstract

摘要

相似文献

Effectiveness of baloxavir marboxil against influenza in children.

Pediatr Int. 2019 Jun;61(6):616-618. doi: 10.1111/ped.13855. Epub 2019 Jun 13.

The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.

Intern Med. 2020;59(12):1509-1513. doi: 10.2169/internalmedicine.4117-19. Epub 2020 Jun 15.

Baloxavir Marboxil (Xofluza) for Influenza.

Am Fam Physician. 2019 Dec 15;100(12):776-777.

Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.

BMC Infect Dis. 2020 Jul 6;20(1):478. doi: 10.1186/s12879-020-05205-1.

Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.

Ann Pharmacother. 2019 Jul;53(7):754-759. doi: 10.1177/1060028019826565. Epub 2019 Jan 23.

Introducing the new anti-influenza drug, baloxavir marboxil.

Respir Investig. 2020 Jan;58(1):1-3. doi: 10.1016/j.resinv.2019.10.005. Epub 2019 Nov 29.

Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.

Antiviral Res. 2019 Mar;163:75-81. doi: 10.1016/j.antiviral.2019.01.012. Epub 2019 Jan 23.

Sixty seconds on . . . baloxavir.

BMJ. 2018 Oct 26;363:k4531. doi: 10.1136/bmj.k4531.

Baloxavir: First Global Approval.

Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.

A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.

Curr Med Res Opin. 2019 Aug;35(8):1355-1364. doi: 10.1080/03007995.2019.1584505. Epub 2019 Apr 1.

引用本文的文献

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.

Medicina (Kaunas). 2023 Aug 25;59(9):1543. doi: 10.3390/medicina59091543.

Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.

Microbes Infect. 2020 Jul-Aug;22(6-7):236-244. doi: 10.1016/j.micinf.2020.05.005. Epub 2020 May 13.

Anthralin Suppresses the Proliferation of Influenza Virus by Inhibiting the Cap-Binding and Endonuclease Activity of Viral RNA Polymerase.

Front Microbiol. 2020 Feb 18;11:178. doi: 10.3389/fmicb.2020.00178. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Effectiveness of baloxavir marboxil against influenza in children.

作者信息

Kakuya Fujio, Haga Syunsuke, Okubo Hitoshi, Fujiyasu Hiroaki, Kinebuchi Takahiro

机构信息

Department of Pediatrics, Furano Kyokai Hospital, Furano, Hokkaido, Japan.

Department of Clinical Laboratory, Furano Kyokai Hospital, Furano, Hokkaido, Japan.

出版信息

Pediatr Int. 2019 Jun;61(6):616-618. doi: 10.1111/ped.13855. Epub 2019 Jun 13.

DOI:10.1111/ped.13855

PMID:31195429

Abstract

摘要

相似文献

Effectiveness of baloxavir marboxil against influenza in children.

Pediatr Int. 2019 Jun;61(6):616-618. doi: 10.1111/ped.13855. Epub 2019 Jun 13.

The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice.

Intern Med. 2020;59(12):1509-1513. doi: 10.2169/internalmedicine.4117-19. Epub 2020 Jun 15.

Baloxavir Marboxil (Xofluza) for Influenza.

Am Fam Physician. 2019 Dec 15;100(12):776-777.

BMC Infect Dis. 2020 Jul 6;20(1):478. doi: 10.1186/s12879-020-05205-1.

Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.

Ann Pharmacother. 2019 Jul;53(7):754-759. doi: 10.1177/1060028019826565. Epub 2019 Jan 23.

Introducing the new anti-influenza drug, baloxavir marboxil.

Respir Investig. 2020 Jan;58(1):1-3. doi: 10.1016/j.resinv.2019.10.005. Epub 2019 Nov 29.

Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.

Antiviral Res. 2019 Mar;163:75-81. doi: 10.1016/j.antiviral.2019.01.012. Epub 2019 Jan 23.

Sixty seconds on . . . baloxavir.

BMJ. 2018 Oct 26;363:k4531. doi: 10.1136/bmj.k4531.

Baloxavir: First Global Approval.

Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.

A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.

Curr Med Res Opin. 2019 Aug;35(8):1355-1364. doi: 10.1080/03007995.2019.1584505. Epub 2019 Apr 1.

引用本文的文献

Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir.

Medicina (Kaunas). 2023 Aug 25;59(9):1543. doi: 10.3390/medicina59091543.

Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.

Microbes Infect. 2020 Jul-Aug;22(6-7):236-244. doi: 10.1016/j.micinf.2020.05.005. Epub 2020 May 13.

Anthralin Suppresses the Proliferation of Influenza Virus by Inhibiting the Cap-Binding and Endonuclease Activity of Viral RNA Polymerase.

Front Microbiol. 2020 Feb 18;11:178. doi: 10.3389/fmicb.2020.00178. eCollection 2020.